Thanks GMIN! Interesting how AE37 is mentioned
Post# of 36537
(Total Views: 335)
Posted On: 07/22/2020 6:10:58 PM
Thanks GMIN!
Interesting how AE37 is mentioned on the page 60 of Greenwich LifeSciences S-1/A2020IPO registration (amended)....
Anyone know the connection? Is GNBT/NGIO going to get paid a licensing fee?
Thanks!
GP2 Phase I Clinical Trial — Combination with AE37
• Phase I Safety Trial of the GP2 + GM-CSF Vaccine in Combination with the Helper Peptide AE37 + GM-CSF Vaccine
• 14 patients treated with GP2 + AE37 + GM-CSF
GP2 Phase I Clinical Trial — Combination with AE37
As shown in the table above, a Phase I trial evaluating the combination therapy of GP2 + GM-CSF administered simultaneously with HER2/neu peptide AE37 in 14 clinically disease-free, HER2/neu breast cancer and ovarian cancer patients was conducted. While 28 patients enrolled, 14 patients completed the 6 vaccination series. Initial results suggest that combining GP2 and AE37 peptides is well tolerated at all tested dosing levels. Additionally, we believe the combination is capable of stimulating strong peptide-specific in vivo immune responses.
During the primary vaccination series, an AE37/GP2+GM-CSF dual peptide vaccine resulted in robust T-cell proliferation. However, significant immune responses became more variable at 6 and 12months post vaccination suggesting the need for boosters in some individuals.
GMIN wrote
Check out page 60, also same lawfirm GNBT S1
https://docoh.com/filing/1799788/0001213900-2...light=ae37
Read More: https://investorshangout.com/post/newpost/622...z6Sxp8XYkP
Interesting how AE37 is mentioned on the page 60 of Greenwich LifeSciences S-1/A2020IPO registration (amended)....
Anyone know the connection? Is GNBT/NGIO going to get paid a licensing fee?
Thanks!
GP2 Phase I Clinical Trial — Combination with AE37
• Phase I Safety Trial of the GP2 + GM-CSF Vaccine in Combination with the Helper Peptide AE37 + GM-CSF Vaccine
• 14 patients treated with GP2 + AE37 + GM-CSF
GP2 Phase I Clinical Trial — Combination with AE37
As shown in the table above, a Phase I trial evaluating the combination therapy of GP2 + GM-CSF administered simultaneously with HER2/neu peptide AE37 in 14 clinically disease-free, HER2/neu breast cancer and ovarian cancer patients was conducted. While 28 patients enrolled, 14 patients completed the 6 vaccination series. Initial results suggest that combining GP2 and AE37 peptides is well tolerated at all tested dosing levels. Additionally, we believe the combination is capable of stimulating strong peptide-specific in vivo immune responses.
During the primary vaccination series, an AE37/GP2+GM-CSF dual peptide vaccine resulted in robust T-cell proliferation. However, significant immune responses became more variable at 6 and 12months post vaccination suggesting the need for boosters in some individuals.
GMIN wrote
Check out page 60, also same lawfirm GNBT S1
https://docoh.com/filing/1799788/0001213900-2...light=ae37
Read More: https://investorshangout.com/post/newpost/622...z6Sxp8XYkP
(1)
(0)Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Scroll down for more posts ▼